2. Immunology/Inflammation
  3. NOD-like Receptor (NLR)
  4. Ruscogenin

Ruscogenin, an important steroid sapogenin derived from Ophiopogon japonicus, attenuates cerebral ischemia-induced blood-brain barrier dysfunction by suppressing TXNIP/NLRP3 inflammasome activation and the MAPK pathway. Ruscogenin exerts significant anti-inflammatory and anti-thrombotic activities. Ruscogenin has orally bioactivity.

For research use only. We do not sell to patients.

Ruscogenin Chemical Structure

Ruscogenin Chemical Structure

CAS No. : 472-11-7

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Ruscogenin:

Ruscogenin Related Antibodies

Top Publications Citing Use of Products

View All NOD-like Receptor (NLR) Isoform Specific Products:

View All Isoforms
NLRP3 NLRP1 NOD1 NOD2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ruscogenin, an important steroid sapogenin derived from Ophiopogon japonicus, attenuates cerebral ischemia-induced blood-brain barrier dysfunction by suppressing TXNIP/NLRP3 inflammasome activation and the MAPK pathway. Ruscogenin exerts significant anti-inflammatory and anti-thrombotic activities. Ruscogenin has orally bioactivity[1][2].

IC50 & Target

NLRP3

 

Cellular Effect
Cell Line Type Value Description References
BXPC-3 IC50
7.32 μM
Compound: 48
Anticancer activity against human BXPC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Anticancer activity against human BXPC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 36332549]
SW1990 IC50
8.14 μM
Compound: 48
Anticancer activity against human SW1990 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Anticancer activity against human SW1990 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 36332549]
THP-1 IC50
2.27 μM
Compound: 1
Anticoagulant activity in human THP1 cells assessed as inhibition of TNF-alpha-stimulated tissue factor expression incubated 1 hr before TNFalpha challenge measured after 5 hrs
Anticoagulant activity in human THP1 cells assessed as inhibition of TNF-alpha-stimulated tissue factor expression incubated 1 hr before TNFalpha challenge measured after 5 hrs
[PMID: 20561785]
In Vitro

Ruscogenin (0.01-40 μM; 24 h) increases the cell viability in bEnd.3 cells subjected to OGD/R[1].
Ruscogenin (0.01-10 μM; 24 h) reverts the endothelial barrier leakage, inhibits the expression of IL-Iβ and Caspase-1, and modulats the TXNIP/NLRP3 pathway in bEnd.3 cells subjected to OGD/R[1].
Ruscogenin (0.01-10 μM; 4 h) inhibits the production of ROS, and regulated the MAPK Pathway in bEnd.3 Cells subjected to OGD/R[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ruscogenin Related Antibodies

Cell Viability Assay[1]

Cell Line: bEnd.3 cell
Concentration: 0.01 μM, 0.1 μM, 1 μM, 10 μM, 20 μM, 40 μM
Incubation Time: 24 h
Result: Showed that the cell viability reduction in OGD/R-induced bEnd.3 cell was significantly recovered.

Immunofluorescence[1]

Cell Line: bEnd.3 cell
Concentration: 0.1 μM, 1 μM, 10 μM
Incubation Time: 24 h
Result: Demonstrated increase in the TEER value and inhibition the sodium fluorescein permeability.

Western Blot Analysis[1]

Cell Line: bEnd.3 cell
Concentration: 0.01 μM, 0.1 μM, 1 μM, 10 μM, 20 μM, 40 μM
Incubation Time: 24 h
Result: Demonstrated downregulation of the expression of IL-1β and Caspase-1 proteins, and inhibition in the expressions of NLRP3 and TXNIP.

Immunofluorescence[1]

Cell Line: bEnd.3 cell
Concentration: 0.01 μM, 0.1 μM, 1 μM, 10 μM, 20 μM, 40 μM
Incubation Time: 4 h
Result: Demonstrated reduction in the production of ROS.
In Vivo

Ruscogenin (10 mg/kg; i.g.; 1 time) improves the MCAO/R-induced brain tissue injury and inhibits the expression of IL-1β and Caspase-1 and modulats the TXNIP/NLRP3[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MCAO/R Mice[1]
Dosage: 10mg/kg
Administration: Oral Gavage (i.g.)
Result: Showed smaller infarct size, ameliorating histopathological damage by decreasing the cell loss, and significant increase in CBF (cerebral blood flow) compared to the model group.
Resulted inhibiting the expression of IL-1β and Caspase-1, NLRP3 and TXNIP compared to the model group.
Molecular Weight

430.62

Formula

C27H42O4
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@@]12[C@]([C@@H]3C)([H])[C@](O[C@]34CC[C@@H](C)CO4)([H])C[C@@]1([H])[C@@](CC=C(C[C@@H](O)C5)[C@@]6([C@@H]5O)C)([H])[C@]6([H])CC2
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

Ethanol : 25 mg/mL (58.06 mM; Need ultrasonic)

DMSO : 4.31 mg/mL (10.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3222 mL 11.6112 mL 23.2223 mL
5 mM 0.4644 mL 2.3222 mL 4.6445 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 1.67 mg/mL (3.88 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.59%

SDS (393 KB)

COA (250 KB) HNMR (263 KB) RP-HPLC (242 KB) LCMS (98 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / Ethanol 1 mM 2.3222 mL 11.6112 mL 23.2223 mL 58.0558 mL
5 mM 0.4644 mL 2.3222 mL 4.6445 mL 11.6112 mL
10 mM 0.2322 mL 1.1611 mL 2.3222 mL 5.8056 mL
Ethanol 15 mM 0.1548 mL 0.7741 mL 1.5482 mL 3.8704 mL
20 mM 0.1161 mL 0.5806 mL 1.1611 mL 2.9028 mL
25 mM 0.0929 mL 0.4644 mL 0.9289 mL 2.3222 mL
30 mM 0.0774 mL 0.3870 mL 0.7741 mL 1.9352 mL
40 mM 0.0581 mL 0.2903 mL 0.5806 mL 1.4514 mL
50 mM 0.0464 mL 0.2322 mL 0.4644 mL 1.1611 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ruscogenin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ruscogenin472-11-7NOD-like Receptor (NLR)Cardiovascular DiseaseAnti-inflammationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ruscogenin
Cat. No.:
HY-N0496
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.